Phase 1b/2 Study Shows Promising Tolerability of Ampligen-Imfinzi Combo in Advanced Pancreatic Cancer

AIM ImmunoTech Inc. has made significant progress in the clinical trial of a combination therapy for advanced pancreatic cancer. The company has reported that the first dose level of the Phase 1b/2 study, known as the "DURIPANC" study, has been completed with no severe adverse events or dose-limiting toxicities observed. This study is conducted in collaboration with Erasmus Medical Center in the Netherlands and involves the use of AIM's Ampligen® (rintatolimod) alongside AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab).

The positive safety findings have paved the way for the next dose level to be escalated, with the next group of patients expected to start treatment imminently. The treatment duration for subjects will extend up to 48 weeks, or until there is confirmed disease progression or other criteria for discontinuation are met. The patients' responses will be evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

AIM ImmunoTech is a biopharmaceutical firm dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Their flagship product, Ampligen®, is a first-in-class drug that acts as a dsRNA and a highly selective TLR3 agonist immuno-modulator. It has shown broad-spectrum activity in clinical trials for significant cancers, viral diseases, and immune system disorders.